Di Leo, A <br/><br/>
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Aug 2001 
 - 1081-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1023/a:1011669223035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, Neoplasm<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--chemistry<br/>Chemotherapy, Adjuvant<br/>Confidence Intervals<br/>Cyclophosphamide--administration & dosage<br/>DNA Topoisomerases, Type II--analysis<br/>DNA-Binding Proteins<br/>Epirubicin--administration & dosage<br/>Female<br/>Fluorouracil--administration & dosage<br/>Genes, erbB-2--genetics<br/>Humans<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Predictive Value of Tests<br/>Prognosis<br/>Receptor, ErbB-2--analysis<br/>Retrospective Studies<br/>Treatment Outcome